Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: Bruce Ravelson who wrote (747)	4/15/1999 1:22:00 PM
From: DEER HUNTER	Respond to of 1906

check this out ...csfb says 100 bucks some day. Good timing today to with the stock down hard. Thursday April 15, 9:30 am Eastern Time Csfb Initiates Amgenwith a Strong Buy, Sets $100 Per Share Price Target (This is a headline-only alert, although it will likely be followed by an article soon)

To: Bruce Ravelson who wrote (747)	4/15/1999 2:23:00 PM
From: DEER HUNTER	Read Replies (1) \| Respond to of 1906

Thursday April 15, 1:44 pm Eastern Time RESEARCH ALERT-CSFB starts bio-tech stock coverage NEW YORK, April 15 (Reuters) - Credit Suisse First Boston biotechnology analyst Dr. Alex To, M.D., said Thursday he initiated coverage of several stocks in the sector. -- In research notes, To initiated coverage of Biogen Inc. (Nasdaq:BGEN - news) with a buy rating and set a 12-month price target of 135. -- ''Biogen's near-term fundamentals remain strong, though competitive pressure could moderate Avonex's sales growth later this year.'' -- ''New Product pipeline is still in the early stages.'' -- ''Biogen shares could move up with the biotech group, but substantial downside risk exists at the current price should there be clear signs of Avonex's growth slowing down.'' -- Avonex is used in the treatment of multiple sclerosis. -- Biogen's share price is down 1-1/4 at 103-1/8 on the Nasdaq stock market. -- Initiated coverage of Amgen Inc. (Nasdaq:AMGN - news) with a strong buy and set a 12-month price target of 100. -- ''Epogen and Neupogen expected to show strength in the near-term.'' Epogen is used for kidney dialysis patients, while Neupogen is used for cancer and AIDS patients. Both sell more than $1 billion worth per year. -- ''NESP an excellent vehicle to the worldwide anemia markets, should serve to increase Amgen's growth rate.'' NESP is a second generation Epogen product. -- Says Amgen's new product development pipeline has less to offer after NESP except for Abrelix, developed as a treatment for hormone-responsive prostate cancer and endometriosis. -- Amgen share price is down 3-11/16 at 68-1/4 on Nasdaq. -- Immunex Corp. (Nasdaq:IMNX - news) was started as a strong buy with a 12-month price target of 117. -- ''The continued robust sales growth of Enbrel, a promising new drug for the treatment of rheumatoid arthritis, is expected to propel earnings.'' -- ''Novantrone could be expanded into the multiple sclerosis market.'' Novantrone is currently used to treat various forms of cancer. -- Says new product pipeline is strong. -- Immunex shares were up 3-15/16 at 77-3/16 on Nasdaq. -- Chiron Corp. (Nasdaq:CHIR - news) initiated with a strong buy and 12-month target price of 40. -- Chiron ''is our best biotech investment idea.'' -- ''We project a 25 percent year over year earnings growth. Chiron's return on invested capital is expected to grow 9 percent to 17 percent over the next five years.'' -- ''The standstill agreement between Chiron and Novartis will expire in two stages starting in January 2000. A possible buyout scenario by Novartis may further act as a catalyst to Chiron stock.'' -- Chiron's stock was down 3/16 at 20-3/8 on Nasdaq. -- Affymetrix Inc. (Nasdaq:AFFX - news) initiated with a buy rating and a 12-month price target of 50. -- "As one of the key players in the DNA array field, Affymetrix' GeneChip System is a standard platform for genomics research from which new drug discovery and genetic testing evolve. -- Sees Affymetrix' profitable by the end of year 2000. -- Affymetrix stock price down 1-5/16 at 37-1/2 on Nasdaq. -- Centocor Inc. (Nasdaq:CNTO - news) initiated with a hold rating and a price target of 35. -- ''Initial sales of Remicade for Crohn's disease were somewhat disappointing in our view. Its real potential, however, lies in the possibility of a label expansion for treating rheumatoid arthritis.'' -- Centocor share price down 2-1/8 at 34-1/4 on Nasdaq. -- MedImmune Inc. (Nasdaq:MEDI - news) initiated with a buy rating and a 12-month price target of 65. -- Expects a 40 percent season-over-season sales growth for Synagis, used to help prevent respiratory syncytial virus (RSV). RSV affects both upper and lower respiratory tracts. -- MedImmune is down 3 at 51-1/2 on Nasdaq. -- Initiated Genzyme General Corp. (Nasdaq:GENZ - news) with a strong buy and a 12-month price target of 67. Share price down 3-5/16 at 41-13/16. -- Initiated Genzyme Tissue Repair (Nasdaq:GZTR - news) as a buy with a 12-month price target of 5. Share price is up 1/4 at 2-1/2 on Nasdaq. -- Initiated Genzyme Molecular Oncology (Nasdaq:GZMO - news) with a buy rating and set a 12-month price target of 5. Share price unchanged at 3-1/2 on Nasdaq. -- Initiated Human Genome Sciences Inc. (Nasdaq:HGSI - news) with a buy rating and set a target price of 50. Share price down 1/16 at 36 on Nasdaq